Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(25.33%) (37.07%) (50.39%) (50.60%)

+8 more TTM periods

ROA
(14.13%) (21.64%) (30.56%) (31.00%)
ROIC
(18.94%) (28.42%) (40.13%) (40.39%)
Return on Tangible Assets
(16.82%) (25.79%) (38.23%) (39.37%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(3.48) (4.98) (5.49) (5.93)
Free Cash Flow
(23.61) (33.76) (36.62) (40.10)
Other line items

Show all line items

Columns are period end dates